| |  Online-Ressource |
|---|
| Verfasst von: | Cho, Byoung C. [VerfasserIn]  |
|---|
| | Lu, Shun [VerfasserIn] |
|---|
| | Felip, Enriqueta [VerfasserIn] |
|---|
| | Spira, Alexander I. [VerfasserIn] |
|---|
| | Girard, Nicolas [VerfasserIn] |
|---|
| | Lee, Jong-Seok [VerfasserIn] |
|---|
| | Lee, Se-Hoon [VerfasserIn] |
|---|
| | Ostapenko, Yurii [VerfasserIn] |
|---|
| | Danchaivijitr, Pongwut [VerfasserIn] |
|---|
| | Liu, Baogang [VerfasserIn] |
|---|
| | Alip, Adlinda [VerfasserIn] |
|---|
| | Korbenfeld, Ernesto [VerfasserIn] |
|---|
| | Mourão Dias, Josiane [VerfasserIn] |
|---|
| | Besse, Benjamin [VerfasserIn] |
|---|
| | Lee, Ki-Hyeong [VerfasserIn] |
|---|
| | Xiong, Hailin [VerfasserIn] |
|---|
| | How, Soon-Hin [VerfasserIn] |
|---|
| | Cheng, Ying [VerfasserIn] |
|---|
| | Chang, Gee-Chen [VerfasserIn] |
|---|
| | Yoshioka, Hiroshige [VerfasserIn] |
|---|
| | Yang, James C.-H. [VerfasserIn] |
|---|
| | Thomas, Michael [VerfasserIn] |
|---|
| | Nguyen, Danny [VerfasserIn] |
|---|
| | Ou, Sai-Hong I. [VerfasserIn] |
|---|
| | Mukhedkar, Sanjay [VerfasserIn] |
|---|
| | Prabhash, Kumar [VerfasserIn] |
|---|
| | D'Arcangelo, Manolo [VerfasserIn] |
|---|
| | Alatorre-Alexander, Jorge [VerfasserIn] |
|---|
| | Vázquez Limón, Juan C. [VerfasserIn] |
|---|
| | Alves, Sara [VerfasserIn] |
|---|
| | Stroyakovskiy, Daniil [VerfasserIn] |
|---|
| | Peregudova, Marina [VerfasserIn] |
|---|
| | Şendur, Mehmet A. N. [VerfasserIn] |
|---|
| | Yazici, Ozan [VerfasserIn] |
|---|
| | Califano, Raffaele [VerfasserIn] |
|---|
| | Gutiérrez Calderón, Vanesa [VerfasserIn] |
|---|
| | de Marinis, Filippo [VerfasserIn] |
|---|
| | Passaro, Antonio [VerfasserIn] |
|---|
| | Kim, Sang-We [VerfasserIn] |
|---|
| | Gadgeel, Shirish M. [VerfasserIn] |
|---|
| | Xie, John [VerfasserIn] |
|---|
| | Sun, Tao [VerfasserIn] |
|---|
| | Martinez, Melissa [VerfasserIn] |
|---|
| | Ennis, Mariah [VerfasserIn] |
|---|
| | Fennema, Elizabeth [VerfasserIn] |
|---|
| | Daksh, Mahesh [VerfasserIn] |
|---|
| | Millington, Dawn [VerfasserIn] |
|---|
| | Leconte, Isabelle [VerfasserIn] |
|---|
| | Iwasawa, Ryota [VerfasserIn] |
|---|
| | Lorenzini, Patricia [VerfasserIn] |
|---|
| | Baig, Mahadi [VerfasserIn] |
|---|
| | Shah, Sujay [VerfasserIn] |
|---|
| | Bauml, Joshua M. [VerfasserIn] |
|---|
| | Shreeve, S. Martin [VerfasserIn] |
|---|
| | Sethi, Seema [VerfasserIn] |
|---|
| | Knoblauch, Roland E. [VerfasserIn] |
|---|
| | Hayashi, Hidetoshi [VerfasserIn] |
|---|
| Titel: | Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC |
|---|
| Verf.angabe: | B.C. Cho, S. Lu, E. Felip, A.I. Spira, N.Girard, J.-S. Lee, S.-H. Lee, Y. Ostapenko, P. Danchaivijitr, B. Liu, A. Alip, E. Korbenfeld, J. Mourão Dias, B. Besse, K.-H. Lee, H. Xiong, S.-H. How, Y. Cheng, G.-C. Chang, H. Yoshioka, J.C.-H. Yang, M. Thomas, D. Nguyen, S.-H.I. Ou, S. Mukhedkar, K. Prabhash, M. D'Arcangelo, J.Alatorre-Alexander, J.C. Vázquez Limón, S. Alves, D. Stroyakovskiy, M. Peregudova, M.A.N. Şendur, O. Yazici, R. Califano, V. Gutiérrez Calderón, F. de Marinis, A. Passaro, S.-W. Kim, S.M. Gadgeel, J. Xie, T. Sun, M. Martinez, M. Ennis, E. Fennema, M. Daksh, D. Millington, I. Leconte, R. Iwasawa, P. Lorenzini, M. Baig, S. Shah, J.M. Bauml, S.M. Shreeve, S. Sethi, R.E. Knoblauch, H. Hayashi, for the MARIPOSA Investigators |
|---|
| E-Jahr: | 2024 |
|---|
| Jahr: | June 26, 2024 |
|---|
| Umfang: | 13 S. |
|---|
| Illustrationen: | Illustrationen |
|---|
| Fussnoten: | Gesehen am 05.03.2025 |
|---|
| Titel Quelle: | Enthalten in: The New England journal of medicine |
|---|
| Ort Quelle: | Waltham, Mass. : MMS, 1928 |
|---|
| Jahr Quelle: | 2024 |
|---|
| Band/Heft Quelle: | 391(2024), 16 vom: Okt., Seite 1486-1498 |
|---|
| ISSN Quelle: | 1533-4406 |
|---|
| Abstract: | BACKGROUND: Amivantamab plus lazertinib (amivantamab-lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC). - METHODS: In a phase 3, international, randomized trial, we assigned, in a 2:2:1 ratio, patients with previously untreated EGFR-mutated (exon 19 deletion or L858R), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib (in an open-label fashion), osimertinib (in a blinded fashion), or lazertinib (in a blinded fashion, to assess the contribution of treatment components). The primary end point was progression-free survival in the amivantamab-lazertinib group as compared with the osimertinib group, as assessed by blinded independent central review. - RESULTS: Overall, 1074 patients underwent randomization (429 to amivantamab-lazertinib, 429 to osimertinib, and 216 to lazertinib). The median progression-free survival was significantly longer in the amivantamab-lazertinib group than in the osimertinib group (23.7 vs. 16.6 months; hazard ratio for disease progression or death, 0.70; 95% confidence interval [CI], 0.58 to 0.85; P<0.001). An objective response was observed in 86% of the patients (95% CI, 83 to 89) in the amivantamab-lazertinib group and in 85% of those (95% CI, 81 to 88) in the osimertinib group; among patients with a confirmed response (336 in the amivantamab-lazertinib group and 314 in the osimertinib group), the median response duration was 25.8 months (95% CI, 20.1 to could not be estimated) and 16.8 months (95% CI, 14.8 to 18.5), respectively. In a planned interim overall survival analysis of amivantamab-lazertinib as compared with osimertinib, the hazard ratio for death was 0.80 (95% CI, 0.61 to 1.05). Predominant adverse events were EGFR-related toxic effects. The incidence of discontinuation of all agents due to treatment-related adverse events was 10% with amivantamab-lazertinib and 3% with osimertinib. - CONCLUSIONS: Amivantamab-lazertinib showed superior efficacy to osimertinib as first-line treatment in EGFR-mutated advanced NSCLC. (Funded by Janssen Research and Development; MARIPOSA ClinicalTrials.gov number, NCT04487080.). |
|---|
| DOI: | doi:10.1056/NEJMoa2403614 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1056/NEJMoa2403614 |
|---|
| | DOI: https://doi.org/10.1056/NEJMoa2403614 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Acrylamides |
|---|
| | Adult |
|---|
| | Aged |
|---|
| | Aged, 80 and over |
|---|
| | Aniline Compounds |
|---|
| | Antibodies, Bispecific |
|---|
| | Antineoplastic Agents, Immunological |
|---|
| | Antineoplastic Combined Chemotherapy Protocols |
|---|
| | Carcinoma, Non-Small-Cell Lung |
|---|
| | ErbB Receptors |
|---|
| | Female |
|---|
| | Humans |
|---|
| | Kaplan-Meier Estimate |
|---|
| | Lung Neoplasms |
|---|
| | Male |
|---|
| | Middle Aged |
|---|
| | Morpholines |
|---|
| | Mutation |
|---|
| | Progression-Free Survival |
|---|
| | Protein Kinase Inhibitors |
|---|
| | Pyrazoles |
|---|
| | Pyrimidines |
|---|
| | Quinolines |
|---|
| | Treatment Outcome |
|---|
| K10plus-PPN: | 1919164162 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC / Cho, Byoung C. [VerfasserIn]; June 26, 2024 (Online-Ressource)
